New hemophilia drug may last longer, reducing need for frequent shots

NCT ID NCT06579144

Completed Knowledge-focused Sponsor: Swedish Orphan Biovitrum Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called efanesoctocog alfa in 24 adults with severe hemophilia A. Researchers compared how long it stays in the body versus two existing drugs. Participants received one dose of their usual drug, then later one dose of the new drug, with blood samples taken over several days. The goal was to see if the new drug lasts longer, which could mean fewer injections for patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: efanesoctocog alfa (a longer-lasting clotting factor)
What this could lead to: If this drug lasts longer in the body, people with hemophilia A may need fewer infusions to prevent bleeding.
What could go wrong: This is a small, early-phase study in 24 people. It only measures drug levels, not actual bleeding prevention. The drug may not work better in real life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

blood coagulation disease coagulation protein disease hemophilia A severe hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMOPHILIA A

Contacts and locations

Locations

Sobi Investigational Site

Sofia, Bulgaria
Sobi Investigational Site

Bonn, Germany
Sobi Investigational Site

Milan, Italy
Sobi Investigational Site

A Coruña, Spain
Sobi Investigational Site

Valencia, Spain
Sobi Investigational Site

Zaragoza, Spain
Sobi Investigational site

Frankfurt, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.